[ad_1]
© Reuters.
By Davit Kirakosyan
Investing.com — Right here is your every day Professional Recap of the most important analyst cuts you could have missed since yesterday.
Ascendis Pharma shares plunge on FDA’s recognized deficiencies, analysts downgrade the inventory
Ascendis Pharma (NASDAQ:) was downgraded at Credit score Suisse and Morgan Stanley after the U.S. Meals & Drug Administration (FDA) stated it had recognized deficiencies within the firm’s New Drug Software (NDA) for TransCon PTH (palopegteriparatide) in hypoparathyroidism. In consequence, shares plunged greater than 32% yesterday.
Credit score Suisse downgraded the inventory to Impartial from Outperform and minimize its value goal to $82.00 from $130.00, noting it’s reducing the TransCon PTH PoS to 65% from 90%, in addition to adjusting the timing and ramp of the TransCon PTH launch.
In the meantime, Morgan Stanley downgraded the inventory to Equalweight from Obese and minimize its value goal to $108.00 from $151.00.
InvestingPro customers all the time know first. Begin your free 7-day trial to get on board.
nCino downgraded at Morgan Stanley following This fall earnings outcomes
Morgan Stanley downgraded nCino (NASDAQ:) to Equalweight from Obese and minimize its value goal to $25.00 from $27.00. Shares are down greater than 2% pre-market at this time.
The corporate reported its outcomes final week, with income rising 46% year-over-year to $109.2 million, beating the corporate’s steerage.
Constitution Communications downgraded forward of Q1 earnings announcement
KeyBanc downgraded Constitution Communications (NASDAQ:) to Sector Weight from Obese.
The corporate will report its Q1/23 earnings outcomes on April 28. Wall Avenue analysts count on an EPS of seven.60 and income of $13.61 billion.
3 extra downgrades
Barclays downgraded Certara (NASDAQ:) to Equalweight from Obese with a value goal of $25.00.
Scotiabank downgraded Healthpeak Properties (NYSE:) to Sector Carry out from Sector Outperform and minimize its value goal to $24.00 from $27.00.
Mizuho Securities downgraded IDACORP (NYSE:) to Impartial from Purchase and minimize its value goal to $107.00 from $117.00.
[ad_2]
Source link
